The early successes of the CysticFibrosisFoundation were just about the only lifeline Kathryn Giusti had when she was diagnosed with multiple myeloma in 1996.
CysticFibrosisFoundation, the disease advocacy group that funded the early work on Kalydeco, had always intended to find a way to make the medicine work in patients whose disease was caused by other genes.